PRINCIPLES THERAPY OF ATOPIC DERMATITIS IN CHILDHOOD IN THE ASPECT OF MODERN CONCEPTS OF THE PATHOGENESIS OF THE DISEASE

Cover Page
  • Authors: Murashkin N.N.1,2,3, Ambarchyan E.T.1, Materikin A.I.1
  • Affiliations:
    1. Federal State Autonomous Institution “Scientific Center of Children’s Health” of the Ministry of Health of the Russian Federation
    2. Central state medical academy of department of presidential affairs
    3. M. Sechenov First Moscow State Medical University
  • Issue: Vol 93, No 3 (2017)
  • Pages: 85-88
  • Section: DRUG TREATMENT IN DERMATOVENEROLOGY
  • URL: http://www.vestnikdv.ru/jour/article/view/323
  • DOI: https://doi.org/10.25208/0042-4609-2017-93-3-85-88

Abstract


The article contains data on the key links in the pathogenesis of atopic dermatitis in children. The authors of the article have covered modern approaches to topical therapy of atopic dermatitis in children. Modern algorithms of proactive therapy and control over the course of the disease are presented.

About the authors

N. N. Murashkin

Federal State Autonomous Institution “Scientific Center of Children’s Health” of the Ministry of Health of the Russian Federation; Central state medical academy of department of presidential affairs; M. Sechenov First Moscow State Medical University

Author for correspondence.
Email: m_nn2001@mail.ru

Russian Federation Lomonosovsky prosp., 2, bldg 1, Moscow, 119991, Russia; Marshala Timoshenko str.,19, s.1А, Moscow, 121359, Russia; Trubetskaya str., 8, bldg 2, Moscow, 119991, Russia

E.  T. Ambarchyan

Federal State Autonomous Institution “Scientific Center of Children’s Health” of the Ministry of Health of the Russian Federation

Email: fake@neicon.ru

Russian Federation Lomonosovsky prosp., 2, bldg 1, Moscow, 119991, Russia

A. I. Materikin

Federal State Autonomous Institution “Scientific Center of Children’s Health” of the Ministry of Health of the Russian Federation

Email: fake@neicon.ru

Russian Federation Lomonosovsky prosp., 2, bldg 1, Moscow, 119991, Russia

References

  1. Schultz Larsen F. (1993) The epidemiology of atopic dermatitis. Monographs in allergy 31: 9—28.
  2. Huang C., Sheng Y. Pimecrolimus Cream 1% in the Management of Atopic Dermatitis in Pediatric Patients: A Meta-Analysis. Brandner JM, ed. PLoS ONE. 2014; 9.
  3. Spergel J.M., Paller A.S. Atopic dermatitis and the atopic march. J Allergy Clin Immunol 2003; 112 (Suppl 6): S 118—S127.
  4. Kapoor R., Menon C., Hoffstad O., Bilker W., Leclerc P., Margolis D. The prevalence of atopic triad in children with physician-confirmed atopic dermatitis. J Am Acad Dermatol 2008; 9: 68—73.
  5. Carr W.W. Topical Calcineurin Inhibitors for Atopic Dermatitis: Review and Treatment Recommendations. Paediatric Drugs 2013; 15 (4): 303—310.
  6. Proshutinskaya D.V. Atopicheskiy dermatit u detey. Sovremennyy algoritm lecheniya i kontrolya nad zabolevaniyem. Vestnik dermatologii i venerologii 2016; 2: 65—70. [Прошутинская Д.В. Атопический дерматит у детей. Современный алгоритм лечения и контроля над заболеванием. Вестн дерматол венерол 2016; (2): 65—70.]
  7. Kezic S., Novak N., Jakasa I., et al. Skin barrier in atopic dermatitis. Front Biosci 2014; 19: 542—56. Литература
  8. Werfel T., Heratizadeh A., Niebuhr M., Kapp A., Roesner L.M., Karch A., et al. Exacerbation of atopic dermatitis on grass pollen exposure in an environmental challenge chamber. J Allergy Clin Immunol 2015; 136: 96—103.
  9. Bieber T. Atopic dermatitis. Ann Dermatol. 2010; 22 (2): 125—137.
  10. Hanifin J.M., Paller A.S., Eichenfield L., Clark R. A., Korman N., Weinstein G. et al. US Tacrolimus Ointment Study Group. Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. J Am Acad Dermatol 2005; 53 (2, Suppl. 2): S 186—94.
  11. Simon D., Lubbe J., Wuthrich B., Wiesner A., Weber M.M., Laffitte E., Anliker M.D., Schoni M.H., Braathen L.R., Schmid-Grendelmeier P., Gilgen Bobalj N., Schneider D.: Benefits from the use of pimecrolimus-based treatment in the management of atopic dermatitis in clinical practice: analysis of a Swiss cohort. Dermatology 2006; 213: 313—318.
  12. Mihm M.C., Soter N.A., Dvorak H.F., Austen K.F.: The structure of normal skin and the morphology of atopic eczema. J Invest Dermatol 1976; 67: 305—312.
  13. Bangert C., Strober B.E., Cork M., Ortonne J.P., Luger T., Bieber T., Ferguson A., Ecker R.C., Kopp T., Weise-Riccardi S., Guettner A., Stingl G. Clinical and Cytological Effects of Pimecrolimus Cream 1% after Resolution of Active Atopic Dermatitis Lesions by Topical Corticosteroids: A Randomized Controlled Trial. Dermatology 2011; 222: 36-48.
  14. Carr W.W.: Topical Calcineurin Inhibitors for Atopic Dermatitis: Review and Treatment Recommendations. Paediatr Drugs. 2013 Aug; 15 (4): 303—310.
  15. Arellano F.M., Wentworth C.E., Arana A., Fernandez C., Paul C.F. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol. 2007; 127: 808—816.
  16. Sigurgeirsson B., Boznanski A., Todd G., et al. Safety and eficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial. Pediatrics 2015: 135: 597—606.
  17. Billich A., Aschauer H., Aszodi A., et al. Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm 2004; 269: 29—35.
  18. Kaufmann R., Folster-Holst R., Hoger P., et al. Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants. J Allergy Clin Immunol 2004: 114: 1183—8.
  19. Lübbe J. Secondary infections in patients with atopic dermatitis. Am J Clin Dermatol 2003; 4: 641—54.
  20. Luger T., De Raeve L., Gelmetti C. et al. Recommendations for pimecrolimus 1% cream in the treatment of mild-to-moderate atopic dermatitis: from medical needs to a new treatment algorithm. Eur J Dermatol 2013; 23: 758—66.

Statistics

Views

Abstract - 550

PDF (Russian) - 236

PlumX

Dimensions


Copyright (c)



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies